Daratumumab plus Bortezomib/Lenalidomide/ Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study

被引：0

作者：

Usmani, Saad Z. ^{[1
]}

Facon, Thierry ^{[2
]}

Hungria, Vania ^{[3
]}

Bahlis, Nizar J. ^{[4
]}

Venner, Christopher P. ^{[5
,6
]}

Braunstein, Marc ^{[7
]}

Pour, Ludek ^{[8
]}

Marti, Josep ^{[9
]}

Basu, Supratik ^{[10
,11
]}

Cohen, Yael C. ^{[12
]}

Matsumoto, Morio ^{[13
]}

Suzuki, Kenshi ^{[14
]}

Hulin, Cyrille ^{[15
]}

Grosicki, Sebastian ^{[16
]}

Legiec, Wojciech ^{[17
]}

Beksac, Meral ^{[18
]}

Maiolino, Angelo ^{[19
]}

Liu, Weiping ^{[20
]}

Wang, Jianping ^{[21
]}

Krevvata, Maria ^{[21
]}

Lopez-Masi, Lorena ^{[22
]}

Carey, Jodi ^{[21
]}

Rowe, Melissa ^{[23
]}

Carson, Robin ^{[21
]}

Zweegman, Sonja ^{[24
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

[3] Clin Med Sao Germano, Sao Paulo, Brazil

[4] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[5] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada

[6] Univ British Columbia, BC Canc Vancouver Ctr, Vancouver, BC, Canada

[7] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[8] Univ Hosp Brno, Brno, Czech Republic

[9] Hosp Univ Mutua Terrassa, Terrassa, Spain

[10] Royal Wolverhampton NHS Trust, Wolverhampton, England

[11] Univ Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, England

[12] Tel Aviv Univ, Fac Med & Hlth Sci, Tel Aviv Sourasky Ichilov Med Ctr, Tel Aviv, Israel

[13] Natl Hosp Org, Dept Hematol, Shibukawa Med Ctr, Gunma, Japan

[14] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[15] Univ Hosp, Dept Hematol, Hop Haut Leveque, Pessac, France

[16] Med Univ Silesian, Sch Publ Hlth, Dept Hematol & Canc Prevent, Katowice, Poland

[17] St John Dukla Oncol Ctr Lublin Land, Dept Hematol & Bone Marrow Transplantat, Lublin, Poland

[18] Istinye Univ, Ankara Liv Hosp, Ankara, Turkiye

[19] Inst Amer Ensino Pesquisa & Inovacao, Rio De Janeiro, Brazil

[20] Janssen Res & Dev, Shanghai, Peoples R China

[21] Janssen Res & Dev LLC, Spring House, PA USA

[22] Janssen Res & Dev LLC, Raritan, NJ USA

[23] Janssen Res & Dev LLC, High Wycombe, Bucks, England

[24] Vrije Univ Amsterdam, Dept Hematol, Canc Ctr Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA-63

引用

页码：S288 / S289

页数：2

共 50 条

[41] Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma [J].

Yahiya Y. Syed .

Drugs, 2019, 79 :447-454

[42] A Phase 2 Study of Daratumumab in Combination with Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma [J].

Sanchez, Larysa J. ;

Moshier, Erin ;

Lieberman-Cribbin, Alex ;

Richter, Joshua ;

Richard, Shambavi ;

Rossi, Adriana ;

Rodriguez, Cesar ;

Thibaud, Santiago ;

Cho, Hearn Jay ;

Parekh, Samir ;

Jagannath, Sundar ;

Chari, Ajai .

BLOOD, 2024, 144 :7043-7044

[43] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study [J].

Moreau, Philippe ;

Facon, Thierry ;

Usmani, Saad ;

Bahlis, Nizar Jacques ;

Raje, Noopur ;

Plesner, Torben ;

Orlowski, Robert Z. ;

Basu, Supratik ;

Nahi, Hareth ;

Hulin, Cyrille ;

Quach, Hang ;

Goldschmidt, Hartmut ;

O'Dwyer, Michael ;

Perrot, Aurore ;

Venner, Christopher P. ;

Weisel, Katja ;

Tiab, Mourad ;

Macro, Margaret ;

Frenzel, Laurent ;

Leleu, Xavier ;

Pei, Huiling ;

Krevvata, Maria ;

Carson, Robin ;

Borgsten, Fredrik ;

Kumar, Shaji K. .

BLOOD, 2022, 140 :7297-7300

[44] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study [J].

Moreau, P. ;

Facon, T. ;

Usmani, S. Z. ;

Bahlis, N. ;

Raje, N. ;

Plesner, T. ;

Orlowski, R. Z. ;

Basu, S. ;

Nahi, H. ;

Hulin, C. ;

Quach, H. ;

Goldschmidt, H. ;

O'Dwyer, M. ;

Perrot, A. ;

Venner, C. P. ;

Weisel, K. ;

Tiab, M. ;

Macro, M. ;

Frenzel, L. ;

Leleu, X. ;

Pei, H. ;

Krevvata, M. ;

Carson, R. ;

Borgsten, F. ;

Kumar, S. K. .

ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 :316-317

[45] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study [J].

Moreau, P. ;

Facon, T. ;

Usmani, S. Z. ;

Bahlis, N. ;

Raje, N. ;

Plesner, T. ;

Orlowski, R. Z. ;

Basu, S. ;

Nahi, H. ;

Hulin, C. ;

Quach, H. ;

Goldschmidt, H. ;

O'Dwyer, M. ;

Perrot, A. ;

Venner, C. P. ;

Weisel, K. ;

Tiab, M. ;

Macro, M. ;

Frenzel, L. ;

Leleu, X. ;

Wang, G. ;

Krevvata, M. ;

Carson, R. ;

Borgsten, F. ;

Kumar, S. K. .

ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 :238-238

[46] Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma [J].

Syed, Yahiya Y. .

DRUGS, 2019, 79 (04) :447-454

[47] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone [J].

Mateos, Maria-Victoria ;

Cavo, Michele ;

Blade, Joan ;

Dimopoulos, Meletios A. ;

Suzuki, Kenshi ;

Jakubowiak, Andrzej ;

Knop, Stefan ;

Doyen, Chantal ;

Lucio, Paulo ;

Nagy, Zsolt ;

Pour, Ludek ;

Cook, Mark ;

Grosicki, Sebastian ;

Crepaldi, Andre H. ;

Liberati, Anna Marina ;

Campbell, Philip ;

Shelekhova, Tatiana ;

Yoon, Sung-Soo ;

Iosava, Genadi ;

Fujisaki, Tomoaki ;

Garg, Mamta ;

Krevvata, Maria ;

Wang, Jianping ;

Kudva, Anupa ;

Ukropec, Jon ;

Wroblewski, Susan ;

Kobos, Rachel ;

San-Miguel, Jesus .

BLOOD, 2019, 134

[48] Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients [J].

Ocio, Enrique M. M. ;

Bringhen, Sara ;

Martinez-Lopez, Joaquin ;

San-Miguel, Jesus ;

Oliva, Stefania ;

Rodriguez-Otero, Paula ;

Le Roux, Nadia ;

Dong, Yvonne ;

Doroumian, Severine ;

Mace, Sandrine ;

Mateos, Maria-Victoria .

HEMASPHERE, 2023, 7 (02)

[49] Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma [J].

O'Donnell, Elizabeth K. ;

Laubach, Jacob P. ;

Yee, Andrew J. ;

Redd, Robert ;

Huff, Carol Ann ;

Basile, Frank ;

Wade, Philip M. ;

Paba-Prada, Claudia E. ;

Ghobrial, Irene M. ;

Schlossman, Robert L. ;

Burke, Jill N. ;

Harrington, Cynthia C. ;

Lively, Kathleen J. ;

Lyons, Hannah ;

Munshi, Nikhil C. ;

Anderson, Kenneth C. ;

Richardson, Paul G. ;

Raje, Noopur S. .

BLOOD, 2019, 134

[50] Stem Cell (SC) Yield and Transplant with Daratumumab ± Bortezomib, Lenalidomide and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients in the Phase 3 PERSEUS Study [J].

Sonneveld, Pieter ;

Dimopoulos, Meletios ;

Boccadoro, Mario ;

Hang Quach ;

Ho, P. Joy ;

Beksac, Meral ;

Hulin, Cyrille ;

Antonioli, Elisabetta ;

Leleu, Xavier ;

Mangiacavalli, Silvia ;

Perrot, Aurore ;

Cavo, Michele ;

Belotti, Angelo ;

Broijl, Annemiek ;

Gay, Francesca ;

Mina, Roberto ;

van de Donk, Niels ;

Liu, Yanfang ;

Wang, Jianping ;

Sitthi-Amorn, Anna ;

de Boer, Carla J. ;

Carson, Robin ;

Rodriguez-Otero, Paula ;

Blade, Joan ;

Moreau, Philippe .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 :S246-S246

← 1 2 3 4 5 →